Savery F
Dis Nerv Syst. 1977 Aug;38(8):605-8.
Forty-two patients with Parkinson's disease were given amantadine HC1 (Symmetrel) and placebo in an 18 week double-blind cross-over study to determine if amantadine provided additional benefit when combined with levodopa and carbidopa (Sinemet). Analysis of our results showed that amantadine effected a 92% improvement over baseline in symptom scores and a 95% improvement over baseline in activity impairment scores, compared with corresponding values of 4% and 18% for placebo. The difference between amantadine and placebo was statistically significant. Except for one case of mild livedo reticularis and two of blurred vision in the amantadine group, side effects were generally similar for amantadine and placebo in type and frequency. This study provides new evidence of the importance of combinations of antiparkinson drugs to achieve maximum therapeutic benefit.
在一项为期18周的双盲交叉研究中，42名帕金森病患者被给予盐酸金刚烷胺（Symmetrel）和安慰剂，以确定金刚烷胺与左旋多巴和卡比多巴（息宁）联合使用时是否能带来额外益处。对我们研究结果的分析表明，与安慰剂组相应的4%和18%相比，金刚烷胺使症状评分较基线提高了92%，活动障碍评分较基线提高了95%。金刚烷胺与安慰剂之间的差异具有统计学意义。除金刚烷胺组有1例轻度网状青斑和2例视力模糊外，金刚烷胺和安慰剂的副作用在类型和频率上总体相似。这项研究为抗帕金森药物联合使用以实现最大治疗益处的重要性提供了新的证据。
